What is DOXO-EMCH, and what is its primary application?

DOXO-EMCH is a derivative of Doxorubicin designed for use in ADCs. It offers a stable linker mechanism that allows for targeted drug delivery to cancer cells.

What cancers are targeted by DOXO-EMCH-based ADCs?

DOXO-EMCH-based ADCs are effective against various cancers, including breast, lung, and hematologic malignancies, where targeted Doxorubicin delivery is beneficial.

What are the key benefits of using DOXO-EMCH in ADCs?

DOXO-EMCH enhances the delivery of doxorubicin by improving the drug's stability and solubility. This derivative allows for controlled release at the target site, ensuring higher cytotoxicity within cancer cells and reducing systemic toxicity.

How does DOXO-EMCH improve upon standard doxorubicin therapy?

Unlike free doxorubicin, which can cause significant side effects due to systemic exposure, DOXO-EMCH ensures more precise targeting of tumor cells through the ADC format, leading to better therapeutic outcomes with reduced adverse effects.

Is DOXO-EMCH compatible with all types of antibodies for ADC development?

DOXO-EMCH is typically compatible with antibodies that have accessible thiol groups for conjugation. The maleimide linker reacts with thiols, making it crucial to ensure that the chosen antibody has suitable binding sites.

DOXO-EMCH (CAT#: ADC-P-145)

Linker-Toxin SET, INNO-206 (Aldoxorubicin) is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. Following intravenous administration, doxorubicin prodrug INNO-206 binds selectively to the cysteine-34 position of albumin via its maleimide moiety.

Product Information

CAS NO
151038-96-9

Description
Linker-Toxin SET, INNO-206 (Aldoxorubicin) is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. Following intravenous administration, doxorubicin prodrug INNO-206 binds selectively to the cysteine-34 position of albumin via its maleimide moiety.

Classification
DNA Inhibitors

Molecular Weight
750.75

Purity
95%

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-P-145. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

DOXO-EMCH from Creative Biolabs has been a critical addition to my studies. Its selective binding to albumin via the maleimide moiety provided a targeted approach, improving drug delivery in tumor models.

Excellent

In my cancer research, DOXO-EMCH showed remarkable antineoplastic activity. Its unique prodrug mechanism allowed for precise control over drug release, enhancing therapeutic outcomes.

Excellent

As a linker-toxin in my ADC research, DOXO-EMCH greatly improved the efficacy of the conjugates. The selective binding to albumin resulted in more targeted and controlled drug delivery to tumors.

Excellent

In my cytotoxicity studies, DOXO-EMCH demonstrated potent effects on cancer cells. Its prodrug form allowed for enhanced safety and efficacy in drug administration, leading to more reliable results.

Excellent

DOXO-EMCH played a vital role in my experiments on controlled drug release. The maleimide moiety enabled selective albumin binding, offering an innovative way to deliver doxorubicin directly to cancer cells.

Q: 1: What is DOXO-EMCH, and what is its primary application?
A: DOXO-EMCH is a derivative of Doxorubicin designed for use in ADCs. It offers a stable linker mechanism that allows for targeted drug delivery to cancer cells.
Q: 2: What cancers are targeted by DOXO-EMCH-based ADCs?
A: DOXO-EMCH-based ADCs are effective against various cancers, including breast, lung, and hematologic malignancies, where targeted Doxorubicin delivery is beneficial.
Q: 3: What are the key benefits of using DOXO-EMCH in ADCs?
A: DOXO-EMCH enhances the delivery of doxorubicin by improving the drug's stability and solubility. This derivative allows for controlled release at the target site, ensuring higher cytotoxicity within cancer cells and reducing systemic toxicity.
Q: 4: How does DOXO-EMCH improve upon standard doxorubicin therapy?
A: Unlike free doxorubicin, which can cause significant side effects due to systemic exposure, DOXO-EMCH ensures more precise targeting of tumor cells through the ADC format, leading to better therapeutic outcomes with reduced adverse effects.
Q: 5: Is DOXO-EMCH compatible with all types of antibodies for ADC development?
A: DOXO-EMCH is typically compatible with antibodies that have accessible thiol groups for conjugation. The maleimide linker reacts with thiols, making it crucial to ensure that the chosen antibody has suitable binding sites.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.